Market News & Trends
Fusion Pharmaceuticals Announces $105-Million Financing
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.
Swissfillon AG & Früh Verpackungstechnik AG Enter Strategic Collaboration
Swissfillon AG, a provider of aseptic fill and finish services to pharmaceutical and biotechnology companies, and Früh Verpackungstechnik AG, packaging manufacturer and supplier of medical and pharmaceutical contract packaging solutions, have recently entered into a partnership.
Calithera Biosciences Initiates Phase 1/2 Trial; Part of Pfizer Collaboration
Calithera Biosciences, Inc. recently announced the first patient has been treated in the Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in…
Race Oncology Files IND With FDA for Cancer Drug
Race Oncology Limited recently announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene.…
Skyrizi Approval in Japan Crucial for AbbVie as Biosimilar Competition Looms Large on Humira
At a time when pricing and reimbursement pressure is mounting on its blockbuster RA drug Humira (adalimumab) in the US and biosimilar competition looms large…
Novel Compound for Treating TBI Demonstrates Positive Results
Ischemix, Inc. recently announced significant results from a randomized, double-blinded, placebo-controlled preclinical study of its drug, CMX-2043, for the treatment of TBI. The company plans to…
Swedish Biomimetics 3000 Ltd Invents Groundbreaking Continuous Peptide Manufacturing Process
μLOT is an entirely new approach to manufacturing of therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing. The µLOT technology platform provides…
ExCellThera Announces Clearance by FDA & Health Canada for New Clinical Trials
ExCellThera Inc. recently announced its lead technology, ECT-001, will be used as part of two new clinical trials in patients with high-risk leukemia. The announcement…
Saama Closes $40-Million Financing; Driving Disruption in Clinical Analytics & Drug Development
Saama Technologies, Inc., a leading clinical data analytics platform firm, announced that it has closed a $40 million financing with Perceptive Advisors.
Autolus Therapeutics Unveils Next-Generation Technology & Pipeline
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, recently presented insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development.
Amyris Delivers on First CBD Milestone; Collaboration Worth $300 Million
Amyris, Inc. recently announced it successfully delivered on its first milestone for its cannabinoid partner, LAVVAN, earning its first payment of $10 million, which is part of a $300-million collaboration before future royalty payments.
Cytovation Initiates Clinical Development Program for First-in-Class Agent for Tumor Immunotherapy
Cytovation AS recently announced the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as…
NapaJen Pharma & Astellas Pharma Establish Research Collaboration for Discovery & Development of Novel Oligonucleotides
NapaJen Pharma, Inc. recently announced it has entered into a research collaboration with Astellas Pharma Inc. for the discovery and development of novel oligonucleotide therapeutics.…
Innovate Biopharmaceuticals Reports Financing to Initiate Phase 3 Clinical Trial
Innovate Biopharmaceuticals, Inc. recently announced it closed its previously announced equity financing, resulting in gross proceeds of $9.7 million. The company expects to use the…
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis
Nicox SA recently announced the initiation of a Phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being…
BioAegis Therapeutics Completes Enrollment in Phase 1b/2a Dose-Ranging Safety Study
BioAegis Therapeutics Inc. recently announced it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy for patients…
Altimmune Announces Positive Results From NasoVAX Extension Study
Altimmune, Inc. recently announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated…
Enterome Announces Research Collaboration With Dana-Farber Cancer Institute
Enterome recently announced it has entered into a research and development collaboration with Dana-Farber Cancer Institute to evaluate and develop gut microbiome-derived antigens as potential cancer immunotherapies.
Amphastar Pharmaceuticals Receives ANDA Approval for Multi Dose Vial Drug
Amphastar Pharmaceuticals, Inc. recently announced the US FDA granted approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection 300 mg/3 mL (100 mg/mL) Multiple Dose Vial (MDV).
Aptar Pharma’s Nasal Device Approved by FDA for Breakthrough Treatment
Aptar Pharma recently announce that its Bidose nasal spray device was recently approved by the US FDA for a breakthrough therapy in the field of depression.
